Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > In Vivo CRO Market

In Vivo CRO Market Size

  • Report ID: GMI8993
  • Published Date: Apr 2024
  • Report Format: PDF

In Vivo CRO Market Size

In Vivo CRO Market size was valued at USD 4.7 billion in 2023 and is expected to exhibit growth of 7.8% from 2024 to 2032. One of the primary drivers is the increasing complexity of drug development process, that has led pharmaceutical and biotechnology companies to outsource these services to specialized CROs.


Additionally, the rising prevalence of chronic diseases and the need for innovative therapies have fueled the demand for in vivo studies, further fueling the market growth. Moreover, stringent regulations for drug approvals have increased the reliance on CROs for conducting preclinical in vivo studies to ensure compliance with regulatory standards. Furthermore, the growing trend of personalized medicine and the development of novel biologics and biosimilars have further propelled the demand for in vivo CRO services, driving market growth.

In vivo CRO services refer to the range of research services provided by Contract Research Organizations (CROs) that involve studies conducted on living organisms, typically animals, to assess the safety and efficacy of novel therapeutics. These services often include preclinical studies, such as toxicology, pharmacokinetics, and efficacy studies, conducted to support the development and regulatory approval of new drugs or medical products. In vivo CROs play a crucial role in drug development by providing expertise, facilities, and resources to conduct these studies in compliance with regulatory requirements.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

In vivo CRO market was valued at USD 4.7 billion in 2023 and is set to grow at 7.8% CAGR from 2024 to 2032, driven by the increasing complexity of drug development process.

The bioanalysis & DMPK studies service segment held 40.6% of the market share in 2023 and is set to grow rapidly by 2032, driven by complexity of new drug candidates, including biologics and gene therapies.

North America in vivo CRO market size was USD 2 billion in 2023 and is set to grow at 7.6% CAGR between 2024 – 2032, driven by well-established pharmaceutical and biotechnology industries.

Biocytogen, Charles River Laboratories International Inc. , Crown Bioscience, Evotec SE, GemPharmatech Co. Ltd., IQVIA Inc., Icon Plc, Labcorp Drug Development, Parexel International Corporation among others.

In Vivo CRO Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 470
  • Countries covered: 19
  • Pages: 272
 Download Free Sample